Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kirschner

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Swiss Medical Weekly|February 11, 2022
Surgical management of lung cancer during the COVID-19 pandemic - a narrative review and single-centre reportRaphael S Werner, Andreas Lörtscher, Michaela B Kirschner, et al.
NPJ Systems Biology and Applications|June 7, 2018
A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosisFatemeh Vafaee, Connie Diakos, Michaela B Kirschner, et al.
Cancer Gene Therapy|March 23, 2025
Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequenceGlen Reid, Marissa Williams, Yuen Yee Cheng, et al.
JTCVS Open|January 9, 2025
Intracavitary cisplatin-fibrin followed by irradiation improved tumor control compared to the single treatments in a mesothelioma rat modelMichaela B Kirschner, Mayura Meerang, Vanessa Orlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2021
Alterations in <i>BAP1</i> Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaKathrin Oehl, Bart Vrugt, Ulrich Wagner, et al.
Frontiers in Oncology|July 12, 2021
Tumor Immune Microenvironment and Genetic Alterations in MesotheliomaStefanie Hiltbrunner, Laura Mannarino, Michaela B Kirschner, et al.
Molecular Oncology|December 16, 2014
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesotheliomaMichaela B Kirschner, Yuen Yee Cheng, Nicola J Armstrong, et al.
Plos One|August 27, 2013
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)Casey M Wright, Michaela B Kirschner, Yuen Yee Cheng, et al.
Non-Coding RNA|June 20, 2019
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and SurgeryJelena Kresoja-Rakic, Adam Szpechcinski, Michaela B Kirschner, et al.
British Journal of Cancer|December 12, 2013
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesotheliomaA Linton, Y Y Cheng, K Griggs, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Swiss Medical Weekly|February 11, 2022
Surgical management of lung cancer during the COVID-19 pandemic - a narrative review and single-centre reportRaphael S Werner, Andreas Lörtscher, Michaela B Kirschner, et al.
NPJ Systems Biology and Applications|June 7, 2018
A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosisFatemeh Vafaee, Connie Diakos, Michaela B Kirschner, et al.
Cancer Gene Therapy|March 23, 2025
Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequenceGlen Reid, Marissa Williams, Yuen Yee Cheng, et al.
JTCVS Open|January 9, 2025
Intracavitary cisplatin-fibrin followed by irradiation improved tumor control compared to the single treatments in a mesothelioma rat modelMichaela B Kirschner, Mayura Meerang, Vanessa Orlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2021
Alterations in <i>BAP1</i> Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaKathrin Oehl, Bart Vrugt, Ulrich Wagner, et al.
Frontiers in Oncology|July 12, 2021
Tumor Immune Microenvironment and Genetic Alterations in MesotheliomaStefanie Hiltbrunner, Laura Mannarino, Michaela B Kirschner, et al.
Molecular Oncology|December 16, 2014
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesotheliomaMichaela B Kirschner, Yuen Yee Cheng, Nicola J Armstrong, et al.
Plos One|August 27, 2013
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)Casey M Wright, Michaela B Kirschner, Yuen Yee Cheng, et al.
Non-Coding RNA|June 20, 2019
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and SurgeryJelena Kresoja-Rakic, Adam Szpechcinski, Michaela B Kirschner, et al.
British Journal of Cancer|December 12, 2013
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesotheliomaA Linton, Y Y Cheng, K Griggs, et al.
Pageof 10